Smart drug shows promising results for treatment of metastatic triple-negative breast cancer

https://www.facingourrisk.org/XRAY/smart-drug-shows-promise-for-metastatic-triple-negative-breast-cancer

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1814213

We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is an antibody-drug conjugate, meaning that it combines two different molecules: an antibody that targets certain tumor proteins and delivers SN-38, a chemotherapy drug that can kill tumor cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)

Questions To Ask Your Health Care Provider

Are any new therapies for TNBC appropriate for my treatment?
Do I qualify for any clinical trials?
What are the risks and benefits of participating in a clinical trial?
What is the expected length of progression-free survival for my line of treatment?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.